.png)
Cannabis-Based Pain Medication Enters U.S. Clinical Trial: What Patients Should Know
Reporting credit: This article builds on National NORML’s October 22, 2026, report, “New York: Clinical Trial Underway in US for Cannabis-Based Pain Medication.” Suncoast NORML thanks National NORML for its continued coverage of cannabis science, patient access, and marijuana law reform. Additional study details come from New York’s Office of Cannabis Management.
A U.S. clinical trial will evaluate VER-01, an investigational cannabis-based medication, for chronic pain. As National NORML reports, the research represents another step toward understanding how standardized cannabis medicines might fit into pain treatment.
For patients and advocates, the question is straightforward: Can this treatment provide meaningful relief, and what risks come with it? The trial is designed to help answer those questions.
What Is VER-01?
VER-01 is a proprietary cannabis extract manufactured by Germany-based Vertanical. National NORML describes the formulation as containing 2.5 milligrams of THC alongside standardized percentages of CBD and CBG, or cannabigerol.
National NORML also reports that VER-01 received FDA Breakthrough Therapy Designation following European clinical research. That designation should not be confused with FDA approval to market the medication in the United States.
What Will the U.S. Cannabis Pain Trial Study?
According to the New York State Office of Cannabis Management’s announcement, researchers will study an oral VER-01 solution in people with chronic painful lumbosacral radiculopathy, commonly called sciatica.
Upstate Clinical Research Associates in Williamsville, New York, will participate alongside other research sites across the country. Researchers will compare VER-01 with a placebo, examining pain relief, whether benefits persist, and longer-term safety. The state announcement describes the intended population as patients whose pain has not been adequately managed with non-opioid pain medications.
These details matter. A trial of a defined formulation in a specific patient population can help establish which patients may benefit and under what circumstances.
Why This Research Matters for Cannabis Patients
For Suncoast NORML, research and patient advocacy belong in the same conversation.
Patients deserve clear information about potential benefits, side effects, and the limits of existing evidence. Carefully designed clinical trials can help replace broad claims with more useful answers.
A positive result would need to be interpreted in the context of the medication, condition, and patients studied. It would not automatically establish that every cannabis product produces the same effects. Likewise, an ongoing trial should not be presented as a completed success.
Supporting cannabis research means allowing the evidence to develop—and being honest about what it shows.
What Does This Mean for Florida?
This announcement concerns clinical research, rather than a change to Florida’s medical cannabis program. Florida readers should not interpret it as notice that VER-01 is available through local dispensaries.
The broader policy lesson is relevant here: cannabis policy should make room for serious scientific investigation and informed conversations between patients and healthcare professionals.
Suncoast NORML supports an approach that respects patients, encourages research, and evaluates cannabis through evidence.
Frequently Asked Questions
Is VER-01 approved by the FDA?
The sources discussed here describe an investigational medication undergoing U.S. clinical testing. National NORML reports Breakthrough Therapy Designation, which is distinct from marketing approval.
What condition is being studied?
New York’s announcement identifies chronic painful lumbosacral radiculopathy, commonly called sciatica.
Where can I read the original report?
Credit and acknowledgment: National NORML provided the original news report that prompted this Suncoast NORML article. We encourage readers to visit NORML.org, explore its reporting, and support its work advancing cannabis education and marijuana law reform.
Comments